Hematopoietic and lymphoid system neoplasm

This study tests a combination of three drugs—ipilimumab, nivolumab, and brentuximab vedotin—in people with Hodgkin lymphoma that has returned or not responded to treatment. The drugs work by helping the immune system attack cancer cells and by delivering a toxin directly to them…

This study tests whether adding a targeted drug called ganitumab to standard chemotherapy helps people with newly diagnosed Ewing sarcoma that has spread. The trial includes 312 participants and aims to see if the combination improves survival without the cancer growing back. The…

This study tests whether adding the targeted therapy cabozantinib to standard immunotherapy (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer. About 1,175 adults with kidney cancer that has spread will receive either the usual treatment or the usual …

This study tests two oral drugs, mirdametinib and sirolimus, in people with relapsed or refractory multiple myeloma that has specific RAS gene mutations. The trial has two phases: first to find a safe dose, then to see how well the combo works. Up to 54 adults will take the drugs…

This study tests a combination of two drugs—venetoclax and vincristine—in people with T-cell or B-cell acute lymphoblastic leukemia that has returned or not responded to prior treatment. The goal is to find the safest dose and see if the combo can lead to remission. About 40 adul…

This phase 3 trial compares the usual two-drug therapy (ibrutinib plus obinutuzumab) against a three-drug combo that adds venetoclax in older adults (65+) with untreated chronic lymphocytic leukemia. The goal is to see if the extra drug keeps the cancer away longer and whether pa…

This study tests a new drug called marlotamig (REGN7075) alone or with cemiplimab (Libtayo) and sometimes chemotherapy in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors. About 933 participants are being recruite…

This study tested whether a combination of ibrutinib (a targeted drug) and rituximab works better than standard chemotherapy (FCR) for younger patients with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. About 529 people took part. The main goal was t…

This study tests a combination of three drugs (isatuximab, carfilzomib, and pomalidomide) in adults with multiple myeloma that has come back or is not responding to prior treatments. The goal is to see if this mix can shrink or control the cancer. The trial enrolled 5 participant…

This study tests adding vorinostat, a drug that blocks enzymes cancer cells need to grow, to the standard R-CHOP chemotherapy and antibody therapy for people with newly diagnosed advanced diffuse large B-cell lymphoma (DLBCL). The trial has two parts: first, finding the safest do…

This Phase 3 trial compares a new two-drug combination (sonrotoclax plus zanubrutinib) against a standard therapy (venetoclax plus obinutuzumab) in 652 adults with previously untreated chronic lymphocytic leukemia (CLL). The goal is to see which approach better delays disease pro…

This phase II trial tests whether adding either duvelisib or oral azacitidine to standard chemotherapy improves outcomes for people with certain types of peripheral T-cell lymphoma that have not been treated yet. About 170 participants will receive one of three treatment combinat…

This phase 3 trial studies whether taking lenalidomide (Revlimid) after an autologous stem cell transplant can delay the return of multiple myeloma compared to a placebo. About 460 patients with active myeloma who had a stem cell transplant are involved. The main goal is to see h…

This study follows patients who have already been taking ruxolitinib alone or with panobinostat in earlier trials and are still benefiting. Researchers will track side effects over time to see how safe these drugs are for long-term use. About 296 participants with conditions like…

This phase 2 study tests the drug selinexor against standard treatments in 112 people with myelofibrosis who have already tried JAK inhibitors. The main goal is to see if selinexor can shrink the spleen and improve symptoms. Participants are randomly assigned to receive either se…

This early-phase trial is testing whether adding the targeted drug zanubrutinib to a standard chemotherapy cocktail (R-PolaCHP) is safe and effective for people with newly diagnosed diffuse large B-cell lymphoma. The study aims to find the best dose and watch for side effects. Ab…

This study tests whether adding the drug lenalidomide to standard chemo (R-CHOP) helps people with newly diagnosed, aggressive diffuse large B-cell lymphoma. About 350 patients received either R-CHOP alone or R-CHOP plus lenalidomide. Researchers are tracking how long patients li…

This phase 2 trial tests a combination of three drugs—daratumumab, carfilzomib, and dexamethasone (DKd)—in people with high-risk smoldering multiple myeloma, a pre-cancer condition. The goal is to see if this treatment can prevent or delay the disease from turning into active mul…

This phase 3 trial compares two immunotherapy drugs—nivolumab (Opdivo) and brentuximab vedotin (Adcetris)—when added to standard chemotherapy for people aged 12 and older with newly diagnosed stage III or IV classic Hodgkin lymphoma. The goal is to see which combination better de…

This study compares two drug combinations—melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR)—in 306 newly diagnosed multiple myeloma patients who cannot have high-dose therapy. The goal is to see which combination better delays cance…

This phase 3 trial is testing whether adding venetoclax to a standard two-drug regimen (ibrutinib and obinutuzumab) helps younger patients with chronic lymphocytic leukemia (CLL) live longer without their cancer getting worse. The study involves 720 participants who have not yet …

This phase 2 trial tests whether a combination of four drugs—daratumumab, bortezomib, lenalidomide, and dexamethasone—can stop high-risk smoldering multiple myeloma from progressing to active multiple myeloma. Participants must be 18 or older and meet specific high-risk criteria.…

This study tests a combination of two oral drugs, D-1553 and IN10018, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find the best dose and see if the combination can shrink tumors or slow their growth. About 140 adults w…

This study tests whether adding the drug venetoclax to standard chemotherapy can keep high-grade B-cell lymphomas from returning or getting worse. The trial includes 363 people with aggressive lymphoma subtypes. Venetoclax targets a protein that helps cancer cells survive, while …

This study tests whether the drug cabozantinib can slow the growth of advanced neuroendocrine tumors (including carcinoid tumors) compared to a placebo. About 298 adults whose cancer worsened after prior treatment will receive either cabozantinib or a placebo pill. The main goal …

This study tests an experimental drug called selinexor in adults with diffuse large B-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the drug can shrink tumors or control the disease. Participants must have no other proven treatment opt…

This Phase 3 trial is testing whether adding the drug quizartinib to standard chemotherapy helps adults with newly diagnosed acute myeloid leukemia (AML) that lacks a specific genetic mutation (FLT3-ITD). About 700 participants will receive either quizartinib or a placebo alongsi…

This phase 2 trial compares two standard CML drugs—imatinib (Gleevec) at two different doses and dasatinib (Sprycel)—in 406 newly diagnosed patients with chronic phase CML. The main goal is to see which treatment leads to the best molecular response after 12 months, meaning a ver…

This study is for people with a type of slow-growing lymphoma (grades 1-3a) that has returned or not responded to earlier treatment. It tests whether adding other drugs to a standard immunotherapy (obinutuzumab) can improve results. About 73 adults will receive different treatmen…

This study tests whether adding the oral drug selinexor to standard chemotherapy (R-GDP) can help people with relapsed or refractory diffuse large B-cell lymphoma who cannot receive a stem cell transplant or CAR-T therapy. About 500 participants will receive either selinexor at o…

This study compares the standard drug azacitidine alone versus azacitidine combined with either lenalidomide or vorinostat in 282 patients with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The goal is to see if any combination improves re…

This study tests an experimental oral drug called LY3410738 in people with advanced blood cancers such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) that have specific IDH1 or IDH2 gene mutations. The drug is designed to block the mutated IDH proteins that he…

This study tests a two-step treatment for people with relapsed or refractory B-cell Non-Hodgkin lymphoma. First, patients receive a bispecific antibody therapy (Obinutuzumab and Glofitamab) to help the immune system attack cancer cells. Then, they get an infusion of CD19-CAR T ce…

This phase 3 trial tests whether iberdomide is better than lenalidomide as maintenance therapy after a stem cell transplant in people newly diagnosed with multiple myeloma. About 1,200 participants will receive either drug to see which one delays cancer progression longer. The st…

This study tests a new approach for people receiving a stem cell transplant from a partially matched family donor. The donor's immune cells (T cells) are modified in the lab to include a 'suicide gene' that can be activated by a drug if the cells attack the patient's body, causin…

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…

This phase 3 trial tests a new drug, belantamab mafodotin, against a standard treatment (pomalidomide plus dexamethasone) in 325 people with multiple myeloma that has returned or stopped responding to prior therapy. The main goal is to see if the new drug delays cancer progressio…

This study tested a combination of two drugs, azacitidine and gemtuzumab ozogamicin, in 133 older adults (age 60+) with untreated acute myeloid leukemia. The goal was to see how well the treatment could put the cancer into remission and improve survival. The approach uses chemoth…

This study tests a new treatment for a rare and aggressive blood cancer called primary plasma cell leukemia. The approach combines chemotherapy, a stem cell transplant, and two infusions of specially engineered immune cells (CAR-T cells) that target the cancer. The goal is to see…

This study tests a combination of two drugs, ixazomib and rituximab, in people with slow-growing B-cell non-Hodgkin lymphoma. The goal is to see how well the drugs shrink or control the cancer. About 33 adults with different types of this lymphoma are taking part.

This study tests the drug ruxolitinib (Jakafi) in 29 people with chronic myelomonocytic leukemia (CMML), a rare blood cancer. The goal is to see if the drug can improve blood counts, shrink the cancer, or delay its turning into a more aggressive leukemia. Researchers are also che…

This trial tests whether specially modified T cells from a partially matched donor can help patients recover their immune system faster after a stem cell transplant. The T cells are engineered with a 'suicide gene' that allows doctors to destroy them if they cause graft-versus-ho…

This phase 2 trial tested the drug ivosidenib in children and young adults (ages 1 to 21) with solid tumors, lymphomas, or histiocytic disorders that have an IDH1 mutation and have either come back after treatment or not responded. The goal was to see if the drug could shrink or …

This study is for people with follicular lymphoma, a type of blood cancer, that has come back or no longer responds to treatment. It tests whether adding the drug tazemetostat to standard therapy (lenalidomide plus rituximab) helps keep the cancer from growing longer than the sta…

This study tests a drug called belantamab mafodotin in people with multiple myeloma that has come back or stopped responding to treatment, and who also have kidney problems—from mild impairment to end-stage disease requiring dialysis. The drug is an antibody-drug conjugate that t…

This early-stage trial is testing a new drug called AOH1996 in 12 adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The drug works by blocking a protein that helps cancer cells grow and repair themselves. The main goals are to fi…

This phase 1 trial is testing a combination of total marrow and lymphoid irradiation (TMLI) plus two chemotherapy drugs, fludarabine and melphalan, given before a donor stem cell transplant. The goal is to find the safest dose of radiation that can kill cancer cells while prepari…

This study tests a precise radiation method called total marrow and lymphoid irradiation (TMLI) given with two chemotherapy drugs (etoposide and cyclophosphamide) before a donor stem cell transplant. The goal is to safely deliver higher radiation doses to the bone marrow to wipe …

This early-phase trial tests a new immune cell therapy called CS1-CAR T cells for people with multiple myeloma that has come back or not responded to treatment. The therapy involves taking a patient's own immune cells, engineering them in a lab to recognize and attack myeloma cel…

This phase 2 trial tests whether adding the drug pomalidomide to standard chemotherapy (daunorubicin and cytarabine liposome) helps people with a newly diagnosed, aggressive form of acute myeloid leukemia (AML) linked to prior bone marrow disorders. About 50 participants will rec…

This trial investigates a new type of immunotherapy called CAR T-cell therapy that targets two proteins, CD19 and CD22, found on B-cell leukemia cells. The therapy is given along with chemotherapy to children and young adults whose leukemia has come back or has not responded to s…

This study tests whether luspatercept works better than epoetin alfa for treating anemia in adults with a certain type of low-risk MDS who have not needed blood transfusions or prior anemia drugs. About 360 participants will receive one of the two drugs, and researchers will trac…

This study tests a combination of two drugs, polatuzumab vedotin and rituximab, as a first treatment for a rare cancer called post-transplant lymphoproliferative disorder (PTLD) that can occur after an organ or stem cell transplant. The goal is to see if this combo is safe and ef…

This early-stage trial is testing a new oral drug called SNDX-5613 alongside standard intensive chemotherapy in people newly diagnosed with acute myeloid leukemia (AML) that has specific genetic changes (KMT2A, NPM1, or NUP98). The study aims to see if the combination is safe and…

This study tests a condensed version of a chemotherapy regimen (busulfan, melphalan, fludarabine) plus an immune-suppressing drug (ATG) given before a donor stem cell transplant. The goal is to see if this shorter approach causes fewer severe side effects within 30 days after tra…

This Phase 3 trial is testing whether a targeted immunotherapy drug called blinatumomab, given alongside low-intensity chemotherapy, works better than standard chemotherapy for older adults (55+) with a specific type of acute lymphoblastic leukemia (ALL). The study involves 303 p…

This early-phase trial is testing whether combining three drugs—tazemetostat, zanubrutinib, and an anti-CD20 antibody (rituximab or obinutuzumab)—is safe and effective for people with certain types of lymphoma that have come back or not responded to treatment. The study involves …

This early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …

This study tests whether adding the drug ibrutinib to standard chemotherapy before and after a stem cell transplant helps people with a specific type of lymphoma (activated B-cell diffuse large B-cell lymphoma) that has returned or not responded to treatment. About 94 participant…

This early-stage trial is testing a new drug called valemetostat together with two standard drugs (rituximab and lenalidomide) in 60 adults with follicular lymphoma that has come back or not responded to prior treatment. The main goal is to find a safe dose and check for side eff…

This Phase 3 trial is testing an experimental oral drug called BGB-16673 against standard treatments (bendamustine plus rituximab or high-dose methylprednisolone plus rituximab) in 150 people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymp…

This Phase 3 trial tests whether adding ivosidenib (a targeted pill) to standard azacitidine helps adults with a specific IDH1-mutated acute myeloid leukemia (AML) who cannot have intensive chemotherapy. About 146 participants receive either the combo or a placebo plus azacitidin…

This phase 2 trial is testing a new drug called zilovertamab vedotin (MK-2140), alone or with another drug nemtabrutinib, in about 189 people with several types of B-cell blood cancers that have come back or not responded to prior treatments. The main goals are to see if the trea…

This study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…

This study tests a combination of two drugs, neratinib and valproate, in people with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose, and the second part focuses on cancers with a RAS mutation, like certain colon and panc…

This early-phase study tests the safety of combining two drugs, moxetumomab pasudotox and rituximab, for people with hairy cell leukemia that has not responded to standard treatment. About 18 adults will receive up to 8 cycles of the drugs through an IV. The main goal is to find …

This trial investigates the best way to treat children with acute myeloid leukaemia (AML) by comparing different chemotherapy drugs and doses. It tests whether adding up to three doses of the targeted drug gemtuzumab ozogamicin to standard chemo is safe and effective. The study a…

This phase 3 trial compares two types of stem cell transplants for children, adolescents, and young adults with acute leukemia or myelodysplastic syndrome (MDS). One uses a half-matched family donor (haploidentical), the other a fully matched unrelated donor. The goal is to see w…

This phase 3 trial compares a shorter chemotherapy regimen (4 cycles) against the standard 6 cycles, both combined with immunotherapy, for people with newly diagnosed, high-tumor-burden follicular lymphoma. The goal is to see if the shorter treatment is just as effective at keepi…

This early study tests a new drug called ABBV-101 in people with several types of non-Hodgkin lymphoma that have come back or not responded to other treatments. The drug is a pill that targets a protein (BTK) involved in cancer growth. The main goals are to find a safe dose and s…

This early-phase trial is testing an experimental antibody called MEDI-570 in 21 people with certain types of T-cell lymphoma that have come back or not responded to treatment. The goal is to find the safest dose and see how the body handles the drug. MEDI-570 works by targeting …

This early-phase trial is testing whether adding the targeted drug ibrutinib to standard chemotherapy can safely treat HIV-positive patients with a type of lymphoma. The study involves 46 participants and aims to find the best dose and check for side effects. If it works, this co…

This study compares two versions of the drug teclistamab—one made with the current process and one with a new process—in 108 people with multiple myeloma that has come back or not responded to treatment. The main goal is to see if the body absorbs and handles both versions the sa…

This study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…

This early-phase trial tests a combination of the targeted drug ibrutinib with several chemotherapy drugs (TEDDI-R) in people with primary CNS lymphoma, a rare and aggressive brain cancer. The study aims to find the safest dose of ibrutinib when used in this cocktail and to see h…

This phase 2 trial tests the safety and effectiveness of avelumab, an immunotherapy drug, in people with thymoma or thymic carcinoma that has progressed after platinum-based chemotherapy. About 56 participants will receive avelumab intravenously every two weeks. The study aims to…

This trial was designed to test a milder conditioning regimen using a radioactive antibody (90Y-Epratuzumab) followed by chemotherapy and a stem cell transplant for adults with CD22-positive B-cell acute lymphoblastic leukemia. The goal was to find the safest dose that still cont…

This study tests an experimental drug called AG-946 (tebapivat) in 87 adults with lower-risk myelodysplastic syndromes (MDS) who have anemia. The goal is to see if the drug can raise hemoglobin levels or help patients go without blood transfusions for at least 8 weeks. Participan…

This early-phase trial tests a drug called lintuzumab-Ac225 in 18 adults with high-risk myelodysplastic syndrome (MDS) that did not improve after standard treatment. The drug is an antibody that seeks out cancer cells and delivers a radioactive payload to kill them. The main goal…

This phase 2 study tests a single infusion of KTE-X19, a CAR T-cell therapy, in 25 Japanese adults whose mantle cell lymphoma or B-cell acute lymphoblastic leukemia has returned or not responded to prior treatments. The goal is to see how well it shrinks tumors and how safe it is…

This Phase 2 trial tests whether the oral drug gilteritinib works better than midostaurin for adults with a specific genetic subtype of acute myeloid leukemia (FLT3-mutated AML). All 181 participants also receive standard chemotherapy. The goal is to see which drug leads to more …

This early-phase trial is testing a combination of three drugs—rituximab, lenalidomide, and ibrutinib—in people with untreated follicular lymphoma. The goal is to find the safest dose and see how well patients tolerate the mix. The study includes 33 participants with stage II to …

This study offers continued access to the drug parsaclisib for people with B-cell cancers who were already benefiting from it in earlier trials. About 112 participants will keep taking the same dose, either alone or with other drugs, to monitor long-term safety and tolerability. …

This phase 3 trial compares a two-drug combination (pevonedistat plus azacitidine) against azacitidine alone in 302 older or unfit adults newly diagnosed with acute myeloid leukemia (AML) who cannot have standard intensive chemotherapy. The main goal is to see if the combination …

This study tests a new combination of drugs (Dara-SVD) for people with high-risk newly diagnosed multiple myeloma. It compares this new combo to the current standard treatment. The goal is to see if the new approach leads to better cancer control. About 70 participants will take …

This phase 2 trial tests whether giving patients with hard-to-treat acute myeloid leukemia (AML) a special type of immune cell—called a cytokine-induced memory-like natural killer (NK) cell—after a stem cell transplant can improve their chances of staying cancer-free. About 60 ad…

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…

This early-phase study is testing a combination of four drugs (belantamab mafodotin, nirogacestat, pomalidomide, and dexamethasone) in 14 people with multiple myeloma that has returned or stopped responding to at least three prior treatments. The main goals are to check safety an…

This early-phase trial is testing whether adding the targeted drug venetoclax to standard chemotherapy can safely treat adults newly diagnosed with acute myeloid leukemia (AML). About 50 participants will receive the combination to find the best dose and see how many achieve remi…

This study tests the drug clofarabine in 25 people with Langerhans cell histiocytosis (LCH) or related disorders that have returned or not improved with standard therapy. The goal is to see if clofarabine can shrink or eliminate disease. Participants receive the drug and are moni…

This study tests an experimental drug called LY2784544 in people with three types of blood cancers known as myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis. The trial enrolls patients who have not responded to, cannot tolerate, or hav…

This early-stage study is testing a combination of two drugs, belantamab mafodotin and feladilimab, in 25 people with relapsed/refractory multiple myeloma who have already tried at least three other treatments. The main goal is to check the safety of the combination and find the …

This study tests a combination of three drugs—radium-223, M3814, and avelumab—in men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bone. The goal is to see if the combination can slow cancer growth better than radium-223 alone. The…

This Phase 2 trial is testing a combination of three drugs—pirtobrutinib, rituximab, and venetoclax—as a first treatment for people with mantle cell lymphoma who have not had any prior therapy. The goal is to see how many patients achieve a complete response (no cancer detected) …

This early-phase study tests a new drug, BI 1831169, given alone or with an immunotherapy (anti-PD-1 antibody) in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find the highest safe dose and see if the treatment shrinks …

This early-stage trial tests a combination of two drugs, duvelisib and nivolumab, in 38 adults with advanced mycosis fungoides or Sezary syndrome (types of skin lymphoma). The goal is to find the safest dose and see if the drugs can shrink tumors. Duvelisib blocks certain enzymes…

This Phase 3 trial tests whether adding the targeted drug acalabrutinib to standard chemotherapy (R-CHOP) helps people with a specific, aggressive type of lymphoma (non-GCB DLBCL) live longer without their cancer getting worse. About 611 adults aged 18 to 75 who have not been tre…

This early-phase trial tests a new drug called sotatercept (ACE-011) combined with standard myeloma drugs lenalidomide or pomalidomide and dexamethasone in 33 patients whose multiple myeloma has returned or stopped responding to treatment. The main goal is to find the safest dose…

This phase II trial tests whether combining three drugs—bendamustine, obinutuzumab, and venetoclax—can improve outcomes for people with untreated mantle cell lymphoma. Bendamustine and venetoclax are chemotherapy drugs that kill or stop cancer cells from growing, while obinutuzum…

This early-phase trial tests whether adding the drug acalabrutinib to CAR T-cell therapy can improve treatment for certain B-cell lymphomas. Acalabrutinib blocks cancer growth pathways, while the CAR T-cells are engineered to attack lymphoma cells. The study involves 23 adults an…

This early-stage trial is testing a combination of two drugs, belantamab mafodotin and isatuximab, in 30 people with relapsed or refractory multiple myeloma. The goal is to find a safe dose and see if the combination can shrink tumors. Participants must have already tried at leas…

This study allows people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study to keep taking it after that study ends. The goal is to see how safe and tolerable the continued treatment is. Only 13 participants are enrolled, and they take the…

This phase 2 trial tests a combination of two immunotherapy drugs, domvanalimab and zimberelimab, in people with five types of advanced rare cancers (peritoneal mesothelioma, gestational trophoblastic tumor, anaplastic thyroid carcinoma, neuroendocrine tumors, and thymic carcinom…

This phase 2 trial tests lenalidomide and rituximab in 120 people with chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if this drug combination can control the disease, especially for those who cannot or choose not to have chemotherapy. Participants…

This study tests whether adding brentuximab vedotin (a drug that delivers cancer-killing substances directly to lymphoma cells) to standard chemotherapy works better than chemo alone for children and young adults with high-risk Hodgkin lymphoma. About 600 participants with stage …

This study tests a new procedure called BEAM (Bariatric Endoscopic Antral Myotomy) to help people with obesity lose weight. The procedure uses a tube down the throat to make small cuts in the stomach muscle, aiming to change how the stomach empties. Twenty adults with a BMI betwe…

This phase I trial tests a new approach for patients with high-risk or recurrent non-Hodgkin lymphoma. After a stem cell transplant, participants receive a single infusion of their own genetically modified T-cells designed to recognize and attack cancer cells. The study aims to f…

This phase II trial tested whether adding veliparib (a targeted drug) to standard chemotherapy (topotecan and carboplatin) helps people with advanced myeloproliferative disorders, acute myeloid leukemia, or chronic myelomonocytic leukemia. The study enrolled 25 adults whose cance…

This study tests a chemotherapy drug called CPX-351 (Vyxeos) in 25 patients under 22 years old who have secondary myeloid neoplasms, a type of blood cancer that develops after previous cancer treatment. Participants receive one or two rounds of CPX-351, followed by a stem cell tr…

This study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…

This early-phase trial is testing a new drug called venetoclax combined with standard chemotherapy drugs for people with aggressive B-cell lymphoma that has come back or stopped responding to treatment. The main goal is to find the highest safe dose of the new combination. About …

This phase 3 trial tests whether a one-time infusion of cilta-cel, a CAR-T cell therapy, works better than standard drug combinations (PVd or DPd) for people with multiple myeloma that has come back and no longer responds to lenalidomide. About 419 participants will be randomly a…

This study tests whether adding two adult cancer drugs, bortezomib and vorinostat, to standard chemotherapy is safe and effective for infants with acute lymphoblastic leukemia (ALL). About 50 newly diagnosed infants will receive the combination. The goal is to see if it reduces l…

This study tests whether combining two drugs, itacitinib and everolimus, can help people with classical Hodgkin lymphoma that has returned or not responded to prior treatments. The trial is open to adults with measurable disease and aims to see how well the combination works in s…

This early-stage trial tests a new treatment called MCARH109 for people with multiple myeloma that has come back or not responded to at least three prior treatments. The therapy uses specially modified immune cells to target a protein on the cancer cells. The main goal is to find…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This early-stage trial tests a new antibody, BAY 3375968, designed to help the immune system fight advanced solid tumors. It works by reducing regulatory T cells that can suppress immune activity. The study will test the drug alone and combined with pembrolizumab in about 129 peo…

This early-phase study tests a new drug called BGB-11417 (sonrotoclax) in people with B-cell blood cancers that have come back or not responded to treatment. The goal is to find the safest dose and see how well it works alone or combined with other drugs. About 437 adults will ta…

This phase 2 trial compares ibrutinib alone versus ibrutinib plus rituximab in 66 patients with relapsed chronic lymphocytic leukemia (CLL). Ibrutinib blocks cancer growth enzymes, while rituximab helps the immune system attack cancer cells. The study aims to see if the combinati…

This pilot study is testing whether the drug luspatercept can help people with lower-risk myelodysplastic syndromes (MDS) need fewer blood transfusions. Ten adults with MDS will receive the drug by injection. The main goal is to see if it is safe and reduces transfusion needs.

This study tests whether adding three targeted antibodies (tafasitamab, retifanlimab, and rituximab) to standard chemotherapy can safely treat people with untreated diffuse large B-cell lymphoma. About 35 adults will receive the antibody combination before and during chemo. The g…

This study tests a treatment made from a patient's own immune cells, which are genetically modified to recognize and attack a protein called CD20 on cancer cells. It is for people with B-cell non-Hodgkin lymphoma that has returned or not responded to prior therapy. The main goals…

This phase 2 trial is testing a combination of two drugs, acalabrutinib and rituximab, in elderly or frail patients who have not yet been treated for mantle cell lymphoma. The goal is to see how well the drugs shrink or control the cancer. The study involves 48 participants aged …

This study tests a new drug called bomedemstat against the best available treatments for people with essential thrombocythemia (a blood disorder causing too many platelets) who did not respond well to or couldn't tolerate the standard drug hydroxyurea. About 340 adults will be ra…

This phase 2 trial tests the drug atezolizumab in 27 people with chondrosarcoma or clear cell sarcoma that cannot be removed by surgery or has spread. Atezolizumab is an immunotherapy that helps the body's immune system attack cancer cells. The main goal is to see if the drug can…

This early-phase trial tests a combination of three drugs—copanlisib, olaparib, and durvalumab—in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the drugs work together to shrink tumors. Only patie…

This study tests a drug called erdafitinib in children and young adults (ages 1 to 21) whose cancers have come back or are not responding to treatment and have specific changes in FGFR genes. The drug works by blocking enzymes that help cancer cells grow. The main goal is to see …

This phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…

This study tests whether adding the drug bortezomib to standard chemotherapy helps children and young adults (ages 1 to 30) with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. About 847 participants received either standard chemo alone or ch…

This study tests a donor stem cell transplant for people with severe immune system problems, like SCID and Wiskott-Aldrich syndrome. The goal is to help the body make healthy blood cells and fight infections. Participants receive donated stem cells to rebuild their immune system.…

This study tests whether adding the targeted drug copanlisib to two immunotherapy drugs (nivolumab and ipilimumab) can better control advanced solid tumors that have changes in the PIK3CA or PTEN genes. About 54 adults with cancers that have spread or cannot be removed will recei…

This study tests three different chemotherapy combinations in people aged 70 or younger with newly diagnosed mantle cell lymphoma, a type of blood cancer. The goal is to see if adding a targeted drug called acalabrutinib to standard chemo improves how well the cancer responds. Ar…

This phase 2 study is testing a risk-adapted approach for children and young adults with classical Hodgkin lymphoma. Depending on their risk level, patients receive different combinations of chemotherapy drugs, with the goal of improving response while reducing side effects. The …

This phase 2 trial tests the drug ibrutinib in 44 people with hairy cell leukemia that has come back after treatment. Ibrutinib works by blocking a protein that helps cancer cells grow. The main goal is to see how many patients achieve remission within 32 weeks.

This study tests whether using each child's unique genetic information to guide treatment can improve outcomes for acute lymphoblastic leukemia and lymphoma. About 790 children aged 1-18 will receive a combination of chemotherapy and newer targeted therapies, such as CAR T cells …

This phase 3 trial tests whether adding nivolumab to standard chemo-immunotherapy improves outcomes for people with newly diagnosed primary mediastinal B-cell lymphoma. About 244 participants will receive either the combination or standard therapy alone. The main goal is to see i…

This early-phase trial tests a combination of copanlisib (a targeted drug) with nivolumab (an immunotherapy) in people with advanced solid tumors or lymphoma. Some participants will also receive a third drug, ipilimumab. The main goals are to find the safest dose and to monitor s…

This early-phase trial tests a new drug called telaglenastat combined with standard radiation and chemotherapy for people with a specific type of brain tumor (IDH-mutated astrocytoma). The goal is to find the safest dose and see if the combination works better than standard treat…

This early-phase trial tests a reduced-intensity stem cell transplant using a half-matched donor and a drug called cyclophosphamide after the transplant to prevent rejection. The goal is to see if this approach is safe enough for patients with advanced myelofibrosis, a serious bo…

This early-stage trial tests a new treatment for people with advanced solid tumors that have a specific marker called CLDN6. The treatment uses specially engineered immune cells (CAR-T cells) that target CLDN6, sometimes combined with a genetic booster (RNA-LPX) to enhance their …

This large phase 3 study tests whether adding the drug blinatumomab to standard chemotherapy can improve outcomes for children and young adults with newly diagnosed B-cell acute lymphoblastic leukemia or lymphoma, including those with Down syndrome. The trial enrolls over 6,700 p…

This study provides extended access to the drug momelotinib for 237 people with a type of bone marrow cancer called myelofibrosis. Participants had already been taking momelotinib in earlier studies and had not seen their disease get worse. The goal is to see how safe the drug is…

This study was designed to test a new drug called linvoseltamab combined with standard chemotherapy drugs (bortezomib and lenalidomide) in people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal was to see if this combination, with or wi…

This early-stage trial is testing a new drug called AZD0486 in about 226 people with B-cell non-Hodgkin lymphoma, including types like diffuse large B-cell lymphoma and follicular lymphoma. The drug is a bispecific antibody designed to help the body's immune T-cells recognize and…

This study tests whether a stem cell transplant followed by the drug rituximab works better than rituximab alone for people with mantle cell lymphoma whose cancer is in first complete remission. About 689 adults aged 18 to 70 are taking part. The goal is to see which approach hel…

This study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …

This trial explores whether adding the drug tazemetostat (Tazverik) to standard CAR T cell therapy can help the immune cells better recognize and destroy lymphoma cells. It enrolls people with diffuse large B-cell lymphoma, follicular lymphoma, or mantle cell lymphoma who have al…

This phase 3 trial tests a drug called imetelstat against the best available treatments for people with advanced myelofibrosis whose disease has stopped responding to JAK inhibitors. The study includes 327 participants and aims to see if imetelstat can help them live longer and f…

This early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…

This phase 2 trial is testing a combination of four drugs (carfilzomib, lenalidomide, dexamethasone, and daratumumab) given before and after a stem cell transplant for people with multiple myeloma that has come back after prior treatment. The study includes 41 participants and ai…

This phase 1/2 trial tests the drug acalabrutinib (Calquence) in 49 people with central nervous system lymphoma that has come back or not responded to treatment. Participants take the tablet by mouth twice daily. The study aims to find the safest dose and see if the drug can shri…

This early-phase study tests the safety of the immunotherapy drug atezolizumab given after a patient's own immune cells have been modified and infused back (adoptive cell transfer). It includes 40 adults with advanced blood or solid cancers that no longer respond to standard trea…

This phase II trial tests a personalized cell therapy called tisagenlecleucel (Kymriah) in children and young adults with high-risk B-cell acute lymphoblastic leukemia who still have detectable cancer cells after initial chemotherapy. The treatment involves collecting the patient…

This study tests a drug called ulixertinib in children and teens whose advanced cancers have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or control the tumor. About 20 participants with various solid tumors, lymphomas, or related disor…

This phase 2 trial is testing the drug larotrectinib in children and young adults (ages 1 to 21) with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have a specific genetic change called an NTRK fusion. The cancers have either come back after treatment…

This study tested the drug ensartinib in 13 children and young adults (ages 1–21) whose cancers had come back or did not respond to treatment and had specific ALK or ROS1 gene changes. The goal was to see if the drug could shrink or stop tumor growth. While the drug targets cance…

This study tests two drugs, mosunetuzumab and lenalidomide, together in people with follicular lymphoma, a type of blood cancer. It includes 237 participants and compares giving one drug as a shot under the skin versus through an IV. The goal is to see if the combination is safe …

This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein (CDK2) that helps cancer cells grow. The trial will check safety, find the right dose, and see if the drug shrin…

This phase II trial is studying a combination of chemotherapy (Hyper-CVAD) and the targeted drug dasatinib, with or without a donor stem cell transplant, in 97 adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). The goal is to see how well this approa…

This study tests whether adding the drug selinexor to standard chemotherapy can help older adults with untreated acute myeloid leukemia (AML) live longer and achieve remission. About 57 participants will receive either standard chemo alone or chemo plus selinexor, followed by mai…

This early-phase trial tests an experimental virus-based treatment called IDOV-Immune in people with advanced solid tumors that have stopped responding to standard treatments. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone. The study fo…

This phase 2 trial tests whether immune cells from donors who have been exposed to CMV can treat persistent CMV infections in patients who have had a stem cell transplant. The study includes 49 participants with CMV that hasn't improved with standard antiviral drugs. The cells ar…

This study tests whether adding the immunotherapy drug pembrolizumab to standard tyrosine kinase inhibitors (TKIs) can eliminate tiny amounts of leftover leukemia cells in people with chronic myeloid leukemia (CML). About 40 adults with CML who still have detectable cancer marker…

This study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other ta…

This Phase 3 trial compares the drug acalabrutinib to a combination of chlorambucil and rituximab in people with previously untreated chronic lymphocytic leukemia (CLL). The study includes 155 participants and measures how long the cancer stays under control (progression-free sur…

This clinical trial compares three different chemotherapy regimens for young adults (ages 18-65) newly diagnosed with low-risk acute myeloid leukemia (AML). One regimen includes a new drug called lisaftoclax combined with standard chemotherapy drugs. The study aims to see which c…

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…

This study tests three different chemotherapy regimens in 450 young adults (ages 15-65) with intermediate- or high-risk acute myeloid leukemia (AML). All regimens include the experimental drug lisaftoclax plus standard chemotherapies. The main goal is to see which combination lea…

This early-phase study tests an experimental drug called INCB177054, given alone or with another drug (retifanlimab), in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Abo…

This study tests a shorter, more intense radiation schedule (hypofractionation) given after complete surgical removal of thymic tumors. The goal is to see if it can prevent the cancer from coming back while causing fewer side effects than standard radiation. About 50 adults with …

This phase 3 trial is testing whether adding the drug glofitamab to a standard chemotherapy combination (Pola-R-CHP) works better than the standard combo alone for people with untreated large B-cell lymphoma. About 1,130 participants will receive either the new combination or the…

This early-phase trial tests whether adding venetoclax to a chemotherapy regimen originally designed for children is safe and effective for adults under 60 with newly diagnosed acute lymphoblastic leukemia (ALL). The study involves 12 participants and focuses on finding the right…

This early-stage study tests a combination of two drugs, avutometinib and defactinib, in children and young adults (ages 3 to 30) with advanced or recurrent solid tumors that have specific genetic changes. The main goal is to find the safest dose with the fewest side effects. The…

This early-phase trial tests a new cell therapy for people with hard-to-treat T-cell leukemia or lymphoma. Researchers take a patient's own immune T-cells, modify them in the lab to recognize and attack cancer cells carrying the CD7 protein, and infuse them back. The main goals a…

This study is for adults with relapsed or refractory multiple myeloma who have already tried at least three other treatments. It tests a combination of four drugs: belantamab mafodotin, nirogacestat, lenalidomide, and dexamethasone. The goal is to find a safe dose and see how wel…

This study was designed to test whether adding olutasidenib to standard chemotherapy drugs could help control certain blood cancers in people with an IDH1 gene mutation. The trial was withdrawn before enrolling any participants, so no results are available.

This early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…

This phase 2 trial tests a combination of six drugs, called the Beach regimen, in 32 adults with relapsed or refractory acute myeloid leukemia (AML). The goal is to see if this mix can bring about remission and improve survival. Participants receive the drugs in a specific schedu…

This study tests a combination of three oral drugs—ixazomib, iberdomide, and dexamethasone—in patients over 70 with multiple myeloma that has returned after initial treatment. The goal is to see how many patients achieve a very good partial response or better. 75 participants wil…

This study looks at whether giving vitamin D supplements to people with newly diagnosed lymphoma or chronic lymphocytic leukemia who have low vitamin D levels can improve their survival and delay the need for treatment. About 565 participants are being given vitamin D3 or a place…

This study is testing a combination of three drugs—obinutuzumab, ibrutinib, and venetoclax—for people with chronic lymphocytic leukemia (CLL) that has come back, not responded to treatment, or is newly diagnosed. The goal is to find the best dose and see how well the combination …

This early-phase trial tests two drugs, mogamulizumab and brentuximab vedotin, given together to people with a rare type of skin lymphoma (CTCL or mycosis fungoides) that has not responded to prior treatment. The main goal is to see if the combination is safe and to find the best…

This phase II trial tests bintrafusp alfa (M7824) in 9 adults with thymoma or thymic carcinoma that returned after platinum-based chemotherapy. Participants receive the drug intravenously every two weeks until their disease worsens or side effects become intolerable. The study ai…

This phase II trial tests a two-step approach for people with relapsed or refractory large B-cell lymphoma who are eligible for a stem cell transplant. First, patients receive tafasitamab (an antibody) plus lenalidomide, followed by tafasitamab combined with ICE chemotherapy. The…

This phase 2 study tests acalabrutinib, a targeted drug, in 107 people with Waldenström macroglobulinemia, a rare blood cancer. The goal is to see how well the drug shrinks tumors and controls the disease. Participants either had prior treatment or are new to therapy and cannot t…

This study tests whether starting luspatercept (Reblozyl) at the maximum approved dose can help people with low-risk myelodysplastic syndromes (MDS) go without red blood cell transfusions for at least 8 weeks. About 106 participants who currently need regular transfusions will re…

This study was designed to test two immunotherapy drugs, nivolumab and ipilimumab, in children and young adults with cancers that returned or didn't respond to treatment and had many genetic mutations. The goal was to see if the drug combination was safe and could shrink tumors. …

This early-phase trial tests the safety of giving patients modified immune cells from a donor to fight B-cell leukemia or lymphoma that has come back after a stem cell or organ transplant. The cells are designed to target a protein called CD19 on cancer cells. Only 19 patients ar…

This study tests a combination of two drugs, avelumab and M6620, in people with advanced solid tumors that have spread or can't be removed by surgery. The tumors must have a specific DNA repair defect. The goal is to find the safest dose and see if the combination can help contro…

This early-phase trial tests whether adding special immune cells called veto cells to a stem cell transplant can help donor cells grow in the patient without causing severe graft-versus-host disease (GVHD). The study includes 16 people with various blood cancers or bone marrow fa…

This phase 3 trial compares two treatment combinations for people newly diagnosed with multiple myeloma who are not planning an immediate stem cell transplant. One group gets lenalidomide plus low-dose dexamethasone, while the other gets those two drugs plus bortezomib. The goal …

This study tests a drug called iberdomide as maintenance therapy for people with multiple myeloma who have had a stem cell transplant. The goal is to see if more patients can stay on treatment for at least a year without the disease getting worse. About 40 adults will take iberdo…

This phase 3 trial tests whether a new combination of drugs—belantamab mafodotin, pomalidomide, and dexamethasone—works better than a standard combo for people with multiple myeloma that has returned or not responded to treatment. The study involves 21 Japanese adults who have al…

This early-phase trial tests a new drug called navtemadlin (KRT-232) combined with two standard drugs (decitabine and venetoclax) for people with acute myeloid leukemia (AML) that has come back, not responded to treatment, or is newly diagnosed. The main goal is to find the safes…

This phase 3 study tests whether adding the targeted drug belantamab mafodotin to standard medications (pomalidomide and dexamethasone) works better than another standard combo for people with multiple myeloma that has come back or stopped responding to treatment. About 302 parti…

This phase 2 trial tests whether the drug iberdomide, taken after CAR-T therapy, can keep multiple myeloma under control longer than just monitoring. About 78 participants will be randomly assigned to receive iberdomide or standard monitoring. The study is currently suspended.

This early-phase trial tests a new treatment for multiple myeloma that has come back or not responded to standard therapies. The treatment uses a patient's own immune cells (T cells) that are modified in the lab using CRISPR gene editing to recognize and attack cancer cells. Abou…

This study looks at whether lower doses of the chemotherapy drug CPX-351 can help older patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that have come back or not responded to other treatments. The goal is to control the disease while being gentler o…

This phase 2 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with newly diagnosed acute myeloid leukemia (AML) achieve a deeper remission. About 49 participants will receive either chemo alone or chemo plus pembrolizumab. The …

This phase 3 study tested whether adding venetoclax to azacitidine helps people with untreated acute myeloid leukemia (AML) who cannot receive standard chemotherapy. About 443 adults took part, with two-thirds receiving the drug combo and one-third getting a placebo plus azacitid…

This early-phase trial tests a new type of CAR-T cell therapy for people with relapsed or hard-to-treat acute lymphoblastic leukemia. The cells are engineered to recognize and kill leukemia cells, but also include a safety switch that can be turned on to calm them down if side ef…

This early study tests whether elotuzumab can help people with a specific type of myelofibrosis, a serious bone marrow disorder. The drug targets a protein on cancer cells to try to improve blood counts, shrink an enlarged spleen, and ease symptoms. The trial includes 15 adults w…

This early-phase trial tests a new type of immunotherapy for people with Hodgkin lymphoma or cutaneous T-cell lymphoma that has returned or not responded to standard treatments. The therapy uses the patient's own T cells, which are genetically modified to recognize and attack can…

This study tests a combination of two drugs, venetoclax and ASTX727, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) who haven't had treatment before. The goal is to find the safest dose and see if the combo can shrink or control …

This study tests a drug called acalabrutinib in 10 people with central nervous system (CNS) lymphoma that has returned or not responded to treatment. The goal is to see if the drug is safe and can shrink tumors. Acalabrutinib is already approved for another type of lymphoma and w…

This study tests a combination of two drugs (peposertib and avelumab) plus a special type of radiation (hypofractionated) in people with advanced solid tumors or liver/bile duct cancers that have spread. The goal is to find the safest dose and see if the combination can shrink tu…

This early-phase trial tests a new drug called M3814 alongside three chemotherapy drugs (mitoxantrone, etoposide, and cytarabine) in 48 adults with acute myeloid leukemia that has returned or not responded to treatment. The main goal is to find the safest dose and understand side…

This early-stage trial tests a combination of two drugs, gilteritinib and momelotinib, for adults with a specific type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goal is to find a safe dose of momelotinib when given with gilteritini…

This phase II trial tests whether adding the targeted drug acalabrutinib to standard R-CHOP chemotherapy improves outcomes for people with untreated mantle cell lymphoma. About 105 participants will receive the combination, then some will proceed to stem cell transplant. The stud…

This study tests two drugs, dabrafenib and trametinib, in people with advanced cancers that have a specific genetic change called a BRAF V600 mutation. The goal is to see if these drugs can shrink tumors or stop them from growing. The trial includes 44 participants with various c…

This study tests whether giving two drugs—acalabrutinib and obinutuzumab—in cycles can control chronic lymphocytic leukemia (CLL) and allow patients to stop treatment for periods of time. About 60 adults with untreated CLL who need therapy will receive the combination. The goal i…

This phase 2 trial tests whether a combination of two oral drugs, encorafenib and binimetinib, works better than the current drug vemurafenib for people with hairy cell leukemia that has a BRAF mutation and has either not responded to treatment or returned. About 28 adults will t…

This study tests a daily oral drug called nemtabrutinib (ARQ 531) in 190 people with blood cancers like lymphoma or leukemia that have come back or not responded to prior treatment. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-phase trial,…

This early-phase study tests a new drug called navtemadlin (KRT-232) combined with standard chemotherapy (cytarabine and idarubicin) in adults with newly diagnosed acute myeloid leukemia (AML). The goal is to find the safest dose and see how well the combination works. About 24 p…

This study tests a two-drug combination (ibrutinib and rituximab) in people with mantle cell lymphoma that has returned or not responded to treatment, or in older adults newly diagnosed. The goal is to shrink or control the cancer. About 113 participants will receive the drugs to…

This study tests whether combining venetoclax with ASTX727 can help control acute myeloid leukemia (AML) in two groups: patients whose cancer returned or didn't respond to prior treatment, and older adults newly diagnosed who cannot handle strong chemotherapy. The drugs work toge…

This early-phase trial is testing a combination of the immunotherapy drug atezolizumab, two chemotherapy drugs (gemcitabine and oxaliplatin), and the targeted antibody rituximab in 24 patients with transformed diffuse large B-cell lymphoma that has come back or stopped responding…

This study tests a combination of brentuximab vedotin plus standard chemotherapy (CHP) in 52 Chinese adults with a rare type of lymphoma called CD30+ peripheral T-cell lymphoma. The goal is to see how well the treatment shrinks tumors and to monitor side effects. Participants rec…

This study tests whether combining pembrolizumab (an immunotherapy) with gemcitabine (a chemotherapy drug) can shrink tumors in people with advanced mycosis fungoides or Sézary syndrome, rare types of skin lymphoma. The trial enrolled 14 adults who had already tried at least one …

This study tests adding the targeted drug sorafenib to standard chemotherapy (busulfan and fludarabine) before a donor stem cell transplant in adults with acute myeloid leukemia that has returned or not responded to treatment. The goal is to find the safest dose of sorafenib and …

This early-stage trial tests an experimental drug called AZD9592, alone or with other cancer drugs, in about 167 adults with advanced solid tumors (including lung, head & neck, and colorectal cancers). The main goals are to check safety, find the right dose, and see if the drug s…

This study tested a two-step drug combination for people newly diagnosed with mantle cell lymphoma, a type of blood cancer that is not curable with standard treatments. Twenty-three patients who were eligible for a stem cell transplant received rituximab and bendamustine followed…

This study was designed to test a new treatment called GT307 for people with advanced solid tumors that have spread or come back after standard therapy. GT307 uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack the cancer. The main goals were to check saf…

This early-phase trial is testing a drug called flotetuzumab in children and young adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatment. Flotetuzumab is an immunotherapy designed to help the body's immune cells find and attack cancer c…

This study tests whether adding the experimental drug talquetamab to standard treatments (daratumumab and pomalidomide) helps people with multiple myeloma that has returned or stopped responding to prior therapy. About 864 adults will receive either the new combination or the usu…

This study looks at whether giving children with hard-to-cure leukemia a transfusion of white blood cells (granulocytes) after a cord blood transplant helps their new immune system grow faster and safer. About 40 children under 16 will receive this extra transfusion, and research…

This phase II trial tests whether a combination of two drugs, azacitidine and venetoclax, can help keep acute myeloid leukemia (AML) in remission after initial treatment. The study enrolls 50 adults whose AML is in first remission but who are not ready for a stem cell transplant.…

This study aimed to test a less intense version of a standard four-drug combination (Dara-RVd) for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal was to see if giving one drug (bortezomib) once a week instead of twice could stil…

This study tests a new drug called orelabrutinib in people with B-cell malignancies, such as certain lymphomas and leukemias. The drug works by blocking a protein that helps cancer cells grow. The trial has two parts: first finding the safest dose, then seeing how well it shrinks…

This study tests a drug called teclistamab in people with multiple myeloma that has come back or stopped responding to treatment. The drug is a special antibody that helps the body's immune cells find and attack cancer cells. About 194 participants will receive the drug to see ho…

This study tests a combination of four drugs (daratumumab, carfilzomib, pomalidomide, and dexamethasone) in people whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to see how many patients achieve tumor shrinkage and how long the benefit …

This study tests a drug called MT-2111 (loncastuximab tesirine) in people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least two prior treatments. The trial has two parts: first, to find a safe dose, and second…

This early-phase trial tests the safety of giving patients their own genetically modified T-cells to fight relapsed B-cell acute lymphoblastic leukemia. The study includes children and young adults up to age 26 whose leukemia has returned or is hard to treat. The modified T-cells…

This phase 2 trial tests whether combining venetoclax and azacitidine after a stem cell transplant can prevent leukemia from returning in high-risk patients. About 100 adults aged 18-75 with certain types of acute leukemia who are in remission after transplant will receive the dr…

This study tests a combination of three drugs—isatuximab, pomalidomide, and dexamethasone—at lower doses than usual. It includes 6 patients with multiple myeloma that has returned or not responded to treatment, who are also vulnerable due to age or other health problems. The goal…

This phase 3 study tests whether a combination of two targeted drugs, ibrutinib and venetoclax, works better than the current standard therapy (chlorambucil plus obinutuzumab) for adults with chronic lymphocytic leukemia (CLL) who have not yet been treated. The main goal is to se…

This early-phase study tests whether drinking milk from genetically engineered goats (which produce a human enzyme found in breast milk) can reduce the risk of graft versus host disease—a serious immune reaction—in blood cancer patients receiving a donor stem cell transplant. Abo…

This early-stage trial tests a new drug called MP0533 in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The drug is designed to help the body's immune cells find and attack cancer cells. The study will …

This early-phase trial tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma who have had a stem cell transplant. The treatment uses the patient's own T cells, which are modified in a lab to recognize and attack cancer cells that carry a protein called CD30. The m…

This study tests a new daily pill, asciminib, against several standard drugs for people newly diagnosed with a type of leukemia called CML. About 405 adults will be randomly assigned to receive either asciminib or a standard tyrosine kinase inhibitor (TKI). The main goal is to se…

This early-phase study tests a new drug (JNJ-87801493) combined with immune-activating therapies (T-cell engagers) in about 70 people whose B-cell non-Hodgkin lymphoma has returned or stopped responding to other treatments. The main goals are to check safety and find the best dos…

This early-phase trial is testing a new treatment called JNJ-90009530, a type of CAR-T cell therapy that targets a protein called CD20 on lymphoma cells. The study includes 21 adults with relapsed or refractory B-cell non-Hodgkin lymphoma who have already tried other treatments. …

This early-stage trial tests combinations of the drug daratumumab with two newer bispecific antibodies (talquetamab and teclistamab), with or without pomalidomide, in 290 people with multiple myeloma. The main goal is to find safe doses and understand side effects. Participants m…

This early-phase study tests a new drug, JNJ-87562761, in 17 people with multiple myeloma whose cancer returned or didn't respond to prior treatments. The main goals are to find a safe dose and check for side effects. Participants must have measurable disease and have tried certa…

This early-phase study is testing a combination of two treatments—cilta-cel (a cell therapy) and talquetamab (a drug)—in 11 people with high-risk multiple myeloma that has not responded to prior therapies. The main goal is to check safety and side effects. Researchers will also l…

This early-phase trial tests whether a child's own immune cells, genetically modified to recognize and attack leukemia cells, are safe and can be given in the right dose. Six children and young adults with CD19-positive acute lymphoblastic leukemia that has returned after treatme…

This phase II trial is testing new therapies, including the drug teclistamab, for people with multiple myeloma that has relapsed or not responded to treatment. About 300 participants will be enrolled in an adaptive platform design that allows adding new treatment arms over time. …

This early-stage study tests a new oral drug, JNJ-88998377, in about 58 people with relapsed or refractory B-cell non-Hodgkin's lymphoma (a type of blood cancer). The main goals are to check the drug's safety and find the best dose for future studies. Participants must have measu…

This early-stage trial tests a new drug called talquetamab in 279 people with multiple myeloma that has come back or stopped responding to other treatments. Talquetamab is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to check sa…

This phase 2 trial tests whether combining two drugs—nivolumab and axatilimab—can help people with classical Hodgkin lymphoma that has come back or not responded to prior treatments. The study includes 9 adults who have already tried at least one other therapy. Researchers will m…

This phase 2 trial is testing a combination of three drugs—tafasitamab, lenalidomide, and rituximab—in people aged 80 and older with untreated diffuse large B-cell lymphoma (DLBCL). The goal is to see if this gentler, chemotherapy-free regimen can shrink or eliminate tumors after…

This early-stage study tests a new drug called teclistamab in people with multiple myeloma that has returned or stopped responding to other treatments. The main goal is to find a safe dose and check for side effects. About 300 participants will receive the drug to see how well it…

This phase 2 trial tests whether eltrombopag, a drug already approved for other blood disorders, can improve blood cell counts in people with low-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) who have a mutation in the TET2 gene. Participants take…

This phase 2 trial is testing a drug called elranatamab in 50 people with multiple myeloma that has relapsed or stopped responding after at least one prior treatment. Participants have already tried three main drug classes. The goal is to see if elranatamab can reduce the cancer …

This early study tests a new drug called BI 3923948, given as injections into the tumor, either alone or with a checkpoint inhibitor (ezabenlimab) given by IV. It includes about 60 adults with advanced solid tumors that have spread and are not responding to other treatments. The …

This early-stage study tests a new drug called teclistamab combined with other cancer treatments for people with multiple myeloma, a type of blood cancer. The main goal is to check safety and find the best doses. About 140 participants who have already tried other treatments will…

This study tests whether people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) can safely stop taking acalabrutinib and obinutuzumab once their cancer responds very well, instead of continuing treatment indefinitely. The goal is to reduce serious side…

This phase 2 trial tests whether adding the antibody lacutamab to standard chemotherapy (gemcitabine and oxaliplatin) helps people with relapsed or refractory peripheral T-cell lymphoma. About 49 adults whose tumors have a specific marker (KIR3DL2) will receive either the combina…

This phase 3 trial compares a new CAR-T cell therapy (cilta-cel) plus standard drugs against standard drugs alone for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. About 743 participants will receive either the CAR-T combination or standard …

This early-phase study tests the safety of talquetamab combined with other cancer drugs in 166 people with multiple myeloma, a type of blood cancer. The goal is to find safe doses and check for side effects. Participants must have measurable disease and meet specific lab criteria…

This study tests a new treatment called rapcabtagene autoleucel, a type of CAR-T cell therapy, in adults with certain blood cancers like chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL). Some participants also receive the drug ibrutinib. The goal is to…

This study aimed to find a safe dose of revumenib when given with standard chemotherapy drugs for children and young adults with acute leukemia. It was designed for patients with certain genetic markers. However, the trial was withdrawn before any participants were enrolled, so n…

This early-phase study tests a new treatment for patients with relapsed or hard-to-treat lymphoma in the brain or spinal cord. The therapy uses the patient's own immune cells, modified to recognize and attack cancer cells. The main goals are to check safety and see if the treatme…

This early-stage trial tests a new drug called JNJ-89853413 in 64 people whose acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS) have come back or stopped responding to treatment. The main goal is to check safety and find the right dose, with a second part looking a…

This early-phase trial tests a new treatment for people with a rare and hard-to-treat type of lymphoma that has spread to the brain or spinal cord. The therapy uses the patient's own immune cells, modified to target two markers (CD19 and CD22) on cancer cells, and is given throug…

This study tests a treatment using a patient's own immune cells, modified to find and attack cancer cells that carry a marker called CD19. It is for people with B-cell acute lymphoblastic leukemia that has not responded to standard treatments or has come back. The goal is to see …

This early-phase trial is testing the safety and correct dose of combining two cancer drugs, loncastuximab tesirine and venetoclax, for people with non-Hodgkin lymphoma that has come back or stopped responding to treatment. About 23 adults will participate. The goal is to find a …

This study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over …

This study is testing a new treatment called JNJ-68284528, a CAR-T cell therapy, for people with multiple myeloma. The goal is to see if it can reduce cancer cells to undetectable levels (called minimal residual disease negative). About 210 participants who have already tried oth…

This early-phase study tests a new drug called JNJ-80948543 in people with non-Hodgkin lymphoma or chronic lymphocytic leukemia whose cancer has returned or not responded to other treatments. The drug works by redirecting the body's T-cells to attack cancer cells. The main goals …

This study is for people newly diagnosed with a standard-risk form of multiple myeloma, a blood cancer. Researchers want to see if giving a sequence of advanced cell therapies (Cilta-cel, Tal-D, Tec-D) after initial chemotherapy can lead to a very deep and lasting remission, poss…

This pilot study tests whether giving special immune cells called T-APCs after CAR T cell therapy can help the CAR T cells persist longer in the body and prevent leukemia from returning. It involves 30 children and young adults with relapsed or refractory CD19+ leukemia who have …

This early-stage study tests whether combining two types of immune-boosting drugs (bispecific antibodies and a checkpoint inhibitor) is safe for people with multiple myeloma that has come back or stopped responding to treatment. About 74 participants will receive either talquetam…

This early-phase trial tests two experimental drugs, JNJ-80948543 and JNJ-75348780, given together to people with relapsed or refractory B-cell non-Hodgkin lymphoma. The study involves 19 participants and aims to find the safest dose and check for side effects. It is not yet know…

This early-stage study tests a new drug called bleximenib combined with other leukemia treatments for people with acute myeloid leukemia (AML) that has specific genetic changes (KMT2A or NPM1). The main goals are to find the best dose and check for side effects. About 196 partici…

This Phase 1 trial tests a personalized cell therapy for adults with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. Patients' own immune cells are collected, genetically modified to recognize and attack cancer cells, and then infused back af…

This early-stage study tests a new drug called HRS-3738 in people with two types of blood cancer—non-Hodgkin's lymphoma and multiple myeloma—that have returned or not improved after prior treatments. The main goals are to find a safe dose and check how well the drug works. About …

This early-stage trial is testing a new drug called IDE161, alone or with the immunotherapy pembrolizumab, in adults with advanced solid tumors (like breast, ovarian, prostate, or lung cancer). The main goals are to check safety, find the right dose, and get a first look at wheth…

This phase II trial tests whether ultra low dose radiation, given before or after chemotherapy-free targeted therapy, can help control mantle cell lymphoma that has returned or stopped responding to treatment. About 51 adults with measurable disease will receive the radiation, an…

This study tests whether adding iberdomide (a new oral drug) to standard treatments can eliminate tiny amounts of myeloma cells that remain after a stem cell transplant. About 80 adults with multiple myeloma who still have detectable cancer cells after transplant will receive one…

This phase 2 trial tests four different drug combinations in 373 patients aged 60 and older with untreated mantle cell lymphoma. The goal is to see which combination best delays cancer progression. Patients receive rituximab plus bendamustine, with or without bortezomib, followed…

This phase 3 trial tests whether adding the targeted drug acalabrutinib to standard chemotherapy (bendamustine and rituximab) helps people with untreated mantle cell lymphoma live longer without their cancer getting worse. About 635 patients aged 65 and older are taking part. The…

This early-stage study tests a mix of six drugs (called ViPOR-P) in adults with B-cell lymphomas that came back or didn't respond to prior treatment. The goal is to see if the combination is safe and can shrink tumors. About 34 participants will take pills and receive infusions o…

This trial tests an antibody called epcoritamab in 666 people with B-cell lymphoma that has come back or not responded to treatment. The drug is designed to help the immune system attack cancer cells. The study looks at safety, the right dose, and how well the drug works.

This phase 2 trial tests a combination of three drugs—acalabrutinib, venetoclax, and rituximab—in 108 people with untreated mantle cell lymphoma. The goal is to see if the treatment can make the cancer undetectable in the blood (MRD-negative) after about a year. Those who achieve…

This phase 2 trial tests the drug ipatasertib in 35 adults with advanced cancers (solid tumors, lymphoma, or multiple myeloma) that have a specific AKT gene mutation. Ipatasertib is an AKT inhibitor designed to block cancer growth signals. The main goal is to see if the drug can …

This study tests a new way to treat children and young adults with high-risk blood cancers like leukemia and lymphoma. Doctors take blood cells from a family donor, remove certain T cells that can cause a harmful immune reaction, and then transplant the modified cells. The goal i…

This study tests whether adding pevonedistat to standard chemotherapy (cytarabine and idarubicin) can improve remission rates in people newly diagnosed with high-risk acute myeloid leukemia (AML). About 53 participants will receive the combination to find the best dose and check …

This study tests an experimental antibody called epcoritamab, which helps the immune system target and kill cancer cells. It is being tested alone or with other drugs in about 194 people with relapsed/refractory chronic lymphocytic leukemia (CLL) or Richter's syndrome. The goal i…

This study compares a targeted immune therapy called blinatumomab to standard chemotherapy in 669 children and young adults (ages 1-30) whose B-cell acute lymphoblastic leukemia has returned after initial treatment. The goal is to see if blinatumomab can keep the cancer away long…

This study tests whether adding the drug venetoclax to standard chemotherapy can help treat acute lymphoblastic leukemia (ALL). It includes older adults (60+) with newly diagnosed ALL and adults (18+) whose leukemia has come back or not responded to treatment. The goal is to find…

This study tests a drug called epcoritamab, alone or with other treatments, in people with B-cell non-Hodgkin lymphoma, a type of blood cancer. The goal is to find the best dose and see how well it works. About 543 participants will receive the drug under the skin or through an I…

This phase 2 trial tests a new approach for people newly diagnosed with multiple myeloma who have a high-risk genetic change (P53 abnormality). The treatment combines standard chemotherapy with a double dose of specially engineered immune cells (CAR-T cells) and a stem cell trans…

This study tests whether adding an immunotherapy drug (pembrolizumab) to standard chemotherapy (azacitidine and venetoclax) can improve outcomes for older adults with newly diagnosed acute myeloid leukemia (AML) who cannot have intensive chemo. About 60 participants will be rando…

This study looks at whether choosing stem cell donors based on certain genes (KIR) in addition to standard matching can reduce the chance of leukemia returning after a bone marrow transplant. About 511 people with acute myeloid leukemia (AML) are taking part. Doctors will test do…

This study tests a combination of four drugs (carfilzomib, lenalidomide, dexamethasone, and isatuximab) in 50 adults newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see how many patients achieve a complete response after four trea…

This early-phase trial tests a new therapy for Hodgkin and non-Hodgkin lymphoma that has returned or not responded to standard treatment. Researchers take a patient's own immune cells, train them in the lab to recognize five cancer-specific proteins (tumor-associated antigens), a…

This study tests a pill called ruxolitinib for people whose immune system attacks their bone marrow, causing conditions like severe anemia. The drug aims to stop this attack and help the bone marrow recover. Participants take the pill twice daily for up to 6 months and are follow…

This trial tests a drug called epcoritamab in about 78 Japanese adults with B-cell lymphoma that has returned or not improved after standard treatment. The study has two parts: first, finding a safe dose, and then checking how well the drug works alone or with other chemotherapy.…

This early-phase study tests a new drug called uproleselan combined with two standard chemotherapy drugs for children and teens with acute myeloid leukemia or related blood cancers that have returned or not responded to treatment. The drug works by blocking a protein that helps c…

This phase 2 trial tests a drug called mosunetuzumab, given as a shot under the skin, for people with certain types of non-Hodgkin lymphoma. The study includes 320 participants and aims to see if the drug can shrink tumors or delay cancer growth. Researchers are also checking for…

This early-stage study tests an experimental drug called RO7567132, alone or with another drug (atezolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shr…

This study tests whether adding the drug itacitinib to the usual two-drug regimen (cyclophosphamide and tacrolimus) can better prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers. GVHD is a serious complication where donor cells at…

This study tests a new treatment called Orca-T for people with advanced blood cancers like leukemia. It uses a special mix of stem cells and immune cells from a donor to help the body accept the transplant while reducing serious side effects like graft-versus-host disease. The go…

This early-phase study tests whether adding mosunetuzumab after a stem cell transplant is safe for people with aggressive B cell lymphoma that has come back or not responded to prior treatments. Mosunetuzumab is an engineered antibody that helps the body's T cells recognize and k…

This study tests a stem cell transplant from a matched unrelated donor for people with advanced blood cancers or blood disorders. Patients get chemotherapy and radiation before the transplant to prepare their body, then take drugs to prevent the donor cells from attacking their o…

This study aimed to test a new CAR-T cell therapy that targets a protein called Igβ on cancer cells in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The trial planned to enroll patients who had already tried at least two other treatments. However, the study …

This early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…

This study tests a drug called sapablursen in 50 adults with polycythemia vera, a rare blood cancer that causes too many red blood cells. Participants currently need regular blood removal (phlebotomy) to manage their condition. The goal is to see if the drug can reduce how often …

This study tests a drug called blinatumomab given after a stem cell transplant to help prevent relapse in people with B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma. About 44 participants will receive the drug as maintenance therapy. The goal is to see if it i…

This study tests a combination of two chemotherapy drugs (CPX-351) plus a targeted drug (quizartinib) in people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The goal is to find the best dose and see if the combo helps control the cancer. About 52…

This early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults w…

This phase 2 trial tests the drug olaparib in 14 adults with acute myeloid leukemia or myelodysplastic syndrome that has returned or not responded to treatment, and whose cancer has a specific change in the IDH gene. Olaparib is a pill that may block enzymes cancer cells need to …

This study tests a new treatment for people with a type of blood cancer called diffuse large B-cell lymphoma that has come back or not responded to prior therapy. The treatment combines two drugs (tafasitamab and lenalidomide) with standard chemotherapy, followed by a stem cell t…

This study tests whether adding the targeted drug ibrutinib to standard chemotherapy (R-CHOP) helps people with a hard-to-treat type of lymphoma called ABC-DLBCL. About 75 adults aged 18-65 with a poor prognosis will receive the combo for 6 cycles, then take ibrutinib alone for 1…

This early-phase trial tests whether adding an oral chemotherapy drug (CC-486) to the immunotherapy nivolumab can help patients with Hodgkin lymphoma whose cancer no longer responds to PD-1 blockers. About 33 adults will receive the combination to find the safest dose and see if …

This study tests whether adding daratumumab to a standard three-drug regimen (carfilzomib, lenalidomide, and dexamethasone) is safe and effective for people newly diagnosed with multiple myeloma. About 69 participants will receive the four-drug combination for eight cycles, follo…

This study tests whether adding sonrotoclax to the standard drug zanubrutinib works better than zanubrutinib alone for adults with untreated chronic lymphocytic leukemia (CLL). About 94 participants will receive either the combination or the single drug. The goal is to see if the…

This study looks at whether children and teens being treated for acute lymphoblastic leukemia can follow a low-glycemic (low-sugar) diet for six months. The goal is to see if this diet is practical and helps manage weight during cancer treatment. About 88 participants will track …

This phase 2 trial compares a drug combo (ASTX727 plus iadademstat) against ASTX727 alone for people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. The study aims to see if adding iadademstat improves complete response rates. However, the trial …

This study tested a simplified care plan for people with acute promyelocytic leukemia (APL), a rare blood cancer. The goal was to see if following easy-to-use guidelines and getting support from APL experts could lower the number of deaths soon after starting treatment. About 200…

This early-phase trial is testing the drug selinexor (KPT-330) in 16 children and young adults with leukemia that has come back or not responded to standard treatments. The main goal is to find the safest dose and understand side effects. The drug works by blocking a protein that…

This phase 2 trial tests a new treatment plan for teenagers and adults with B-cell acute lymphoblastic leukemia. Patients receive immunotherapy before a stem cell transplant using their own cells, followed by a CD22/CD19 CAR-T 'sandwich' to reduce the risk of relapse. The study a…

This early-stage study tested a combination of three immunotherapy drugs (blinatumomab, nivolumab, and ipilimumab) in 28 adults with a severe form of B-cell leukemia that had returned or not responded to prior treatments. The main goal was to find safe doses and identify side eff…

This early-stage trial tests a new drug called HLX43, an antibody-drug conjugate that targets PD-L1, in people with advanced or metastatic solid tumors that have not responded to standard treatments. Participants also receive another immunotherapy drug, serplulimab (HLX10). The m…

This study tests a new drug called englumafusp alfa, which helps the immune system attack cancer cells. It is given together with either obinutuzumab or glofitamab to people whose B-cell non-Hodgkin lymphoma has returned or stopped responding to treatment. The trial has three par…

This early-phase trial is testing whether adding an experimental drug called Q702 to two standard leukemia drugs (azacitidine and venetoclax) is safe for people with relapsed or refractory acute myeloid leukemia (AML). About 17 adults whose leukemia has not responded to or has re…

This phase 3 trial compares two treatments for people with a bone marrow disorder called myelodysplastic syndrome (MDS) who have low red blood cell counts (anemia). One group gets lenalidomide alone, the other gets lenalidomide plus epoetin alfa, a drug that stimulates red blood …

This study was designed to test a new cell therapy called B7H3 CAR-T for people with advanced solid tumors that have a specific marker (B7H3). The goal was to see if the treatment is safe and shrinks tumors. However, the study was withdrawn before enrolling any participants, so n…

This early-phase study tests whether giving a patient's own genetically modified immune cells (CAR T-cells) after high-dose chemotherapy and a stem cell transplant is safe for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. Seve…

This study was designed to test a new type of cell therapy (BCMA-GPRC5D CAR-T) for people with relapsed/refractory multiple myeloma, a blood cancer that had not responded to at least three prior treatments. The goal was to check the treatment's safety and early signs of effective…

This study tested a combination of the immunotherapy drug blinatumomab with either standard chemotherapy or dasatinib and prednisone in adults aged 65 and older with acute lymphoblastic leukemia (ALL). The goal was to see if the combination could improve survival and control the …

This study tests the drug sunitinib in people with advanced cancers that have a specific change in the cKIT gene. Sunitinib works by blocking signals that make cancer cells grow. The trial includes about 10 adults with lymphoma, solid tumors, or multiple myeloma that have not res…

This phase 2 trial is testing the drug osimertinib in 19 patients with advanced cancers (like lymphoma or solid tumors) that have specific EGFR mutations. Osimertinib is a pill that blocks the faulty EGFR protein, which can help stop tumor growth. The study aims to see if the dru…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study is testing a blood screening program to find multiple myeloma and its early stages (MGUS and smoldering myeloma) in Black adults aged 50 and older. Participants get a simple blood test and fill out questionnaires about their experience and knowledge of the disease. Tho…

This study tests whether a special PET scan using a radioactive form of methionine (a natural amino acid) can help doctors see tumors in children and young adults with various cancers, including brain tumors and sarcomas. About 503 participants will be scanned to see if the metho…

This study tests an 8-week online stress management program for health students in Sfax, Tunisia. The program combines cognitive-behavioral therapy and mindfulness meditation through videos, exercises, and motivational messages. Researchers will measure changes in stress, anxiety…

This phase 2 trial tests whether combining neurofeedback (a brain-wave training therapy) with the drug duloxetine can better relieve nerve pain caused by chemotherapy than either treatment alone. About 336 cancer survivors with persistent nerve pain will be randomly assigned to o…

This study looks at whether writing about their experiences can improve the health of Asian American breast cancer survivors. About 192 people who finished cancer treatment in the last 5 years will take part. They will write and report how they feel, and researchers will track an…

This study tests whether an injection made from human fat cells (Tience®) can safely reduce moderate to severe acne scars. Twenty adults aged 18-40 with scars on their cheeks will receive three treatments on one side of the face over three months. Doctors and participants will tr…

This study tests whether a single high dose of psilocybin (the active ingredient in magic mushrooms) combined with specialized talk therapy can help people with advanced cancer feel less anxious and more at peace. Fifteen adults with stage IV cancer will receive the treatment and…

This study tests a telemedicine program called FOCUS that helps advanced cancer patients manage common symptoms like trouble sleeping, worry, tiredness, and low mood. The program uses counseling techniques delivered through a phone app. Researchers will enroll 120 adults with adv…

This study looks at whether giving the painkiller hydromorphone slowly or quickly through an IV affects how well it controls cancer pain and how likely it is to be misused. About 84 hospitalized cancer patients with moderate to severe pain will receive both a slow and a fast infu…

This pilot study tests a support program called CASA for people with advanced cancer and their caregivers. The program includes five counseling sessions to help with spiritual well-being and emotional distress. Researchers will enroll 124 participants to see if the program is hel…

This study tests a digital program called MINDSET designed to help newly diagnosed cancer patients cope better with treatment. 440 participants will use either the program or a control, and complete questionnaires and blood tests. The goal is to see if the program improves physic…

This study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…

This study tests whether adding levocarnitine, a natural nutrient, to standard chemotherapy can prevent severe liver damage in teens and young adults (ages 15-39) with leukemia or lymphoma. About 440 participants will receive either chemotherapy alone or chemotherapy plus levocar…

This study explores whether individualized transcranial magnetic stimulation (TMS) can improve symptoms in adults with irritable bowel syndrome (IBS). Participants receive 10 TMS sessions over two weeks, with brain scans and stool tests before and after to understand how the trea…

This study follows nearly 1,900 cancer patients who tested positive for COVID-19. Researchers collect blood samples, medical records, and images to see how the virus impacts their cancer treatment and overall health. The goal is to learn which factors make COVID-19 more severe in…

This study screens up to 10,000 people with blood disorders or healthy volunteers to see if they can safely join other active research studies at the National Heart, Lung, and Blood Institute. Participants undergo clinical, imaging, and lab tests. If no suitable study is availabl…

This study follows nearly 90,000 farmers, their spouses, and pest control workers in Iowa and North Carolina over many years. Researchers track their exposure to pesticides and other farm chemicals, then monitor who develops cancer or other diseases. The goal is to identify which…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study looks at whether cancer survivors can use a smartwatch and a phone app to regularly report their symptoms and activity levels. Fifty adults who have finished cancer treatment and have stable disease will wear a smartwatch for about four months and fill out weekly quest…

This study follows over 64,000 adults who grew up on farms to see if early exposure to pesticides and other agricultural factors is linked to cancer. Participants fill out an online questionnaire and may provide biological samples. Researchers will track their health over many ye…

This study will observe 30 adults in Taiwan with relapsed or refractory multiple myeloma who are taking elranatamab as part of their regular care. Researchers will track how quickly the cancer responds, how long the response lasts, and overall survival. The goal is to understand …

This study follows up to 1,000 adults who previously received gene therapy in a National Cancer Institute study. Researchers will contact participants yearly for up to 15 years to check for any long-term side effects, such as new cancers or nerve problems. No new treatments are g…

This study looks at the cost-effectiveness of three treatments for chronic lymphocytic leukemia (CLL) in patients aged 65 and older. Researchers compared ibrutinib alone or with rituximab against bendamustine plus rituximab, measuring both healthcare costs and quality of life. Th…

This study looks at how spirituality — personal beliefs, values, and meaning — influences adults recently diagnosed with blood cancers like lymphoma or leukemia, as well as their loved ones. Participants fill out three questionnaires about spiritual well-being, quality of life, a…

This study looks back at medical records of 500 adults with aggressive B-cell lymphoma that has a MYC gene change. Researchers want to see if a stronger chemotherapy plan called CARMEN leads to better survival and remission rates compared to other treatments. Since it's a review …

This study tracks 56 follicular lymphoma patients to see how long their COVID-19 and other vaccine immunity lasts while they receive chemotherapy and maintenance therapy. Researchers will collect blood samples at several time points to measure immune responses. The goal is to und…

This study tests whether a wearable patch called TempTraq can detect fevers earlier than standard temperature checks in cancer patients receiving immunotherapy. The goal is to see if continuous monitoring reduces the risk of severe cytokine release syndrome (CRS), a serious side …

This pilot study aimed to see if it is possible to use neuropsychological tests to measure thinking, memory, and emotional health in adults who received CAR-T therapy for aggressive lymphoma at least six months earlier. The study was withdrawn before enrolling any participants, s…

This study looks at the genetic makeup of rare blood diseases like Castleman disease and Langerhans cell histiocytosis. Researchers will analyze blood or tissue samples from 135 participants to find genetic changes that could be targeted by existing or experimental therapies. The…

This study collects blood and bone marrow samples from up to 550 people with blood cancers like leukemia, lymphoma, and myelodysplastic syndrome. Researchers will study the cells, genes, and proteins in these samples to better understand how these cancers develop and to find new …

This study looks at how patients with advanced blood cancers (like acute myeloid leukemia) who are not eligible for a cure, along with their nurses and doctors, feel about the benefits of blood transfusions. Researchers will give questionnaires before each transfusion to compare …

This study tests whether a short simulation training session helps nursing students learn how to manage a complication (extravasation) in an adolescent leukemia patient. 18 third-year nursing students will take part in a 46-minute session that includes a scenario and group discus…

This study looks at how well the drug acalabrutinib works for people with chronic lymphocytic leukemia (CLL) in real-life settings in Romania. Researchers will collect data from 250 patients over three years to see how long they stay on the drug, why they stop, and how effective …

This study is looking at whether a blood test that measures cell-free DNA (cfDNA) can help doctors know how well first-line treatment is working in people with follicular lymphoma. Researchers will collect blood samples before, during, and after standard treatment, and compare cf…

This study examines how common obstructive sleep apnea (OSA) is in adult survivors of Hodgkin lymphoma who received chest radiation. Researchers will compare 220 survivors to matched controls using sleep tests, brain scans, and heart assessments. The goal is to understand links b…

This study aimed to evaluate how community cancer centers test for biomarkers in common solid cancers like breast, lung, and colorectal cancer. Researchers planned to survey pathology practices to see if they follow guidelines for key tests and how quickly results are reported. T…

This study does not provide any new treatment. It follows about 1,000 adults who previously received CAR T-cell gene therapy at the NIH. Researchers will check for long-term side effects through blood tests, clinic visits, and annual phone calls for up to 15 years, as required by…

This study tests a symptom questionnaire designed for teenagers with cancer. Researchers will interview 41 adolescents aged 13-17 to see if the survey accurately captures their symptoms. The goal is to improve how doctors understand and manage symptoms in young cancer patients.

This study follows over 1,500 young adult survivors of childhood cancers like leukemia, brain tumors, and Hodgkin lymphoma to see how frailty—a measure of physical weakness and vulnerability—changes over five years. Researchers want to know if frailty can predict future chronic h…

This study looks at how cancer and its treatment impact social and emotional development in children aged 4 to 6. About 119 children with brain or solid tumors will complete questionnaires and tasks to measure social skills, thinking abilities, and play behavior. The goal is to u…

This study screens children and teens with advanced solid tumors, lymphomas, or histiocytic disorders to find genetic changes in their cancer cells. Participants undergo biopsies and scans to identify mutations that can be targeted by specific drugs. The goal is to see if matchin…

This was a planned French study to collect information on chronic myeloid leukemia (CML) in young adults aged 18 to 30 who were treated with tyrosine kinase inhibitors. The goal was to describe their diagnosis, treatment choices, side effects, and quality of life. However, the st…

This long-term study looks at people and families with a higher chance of developing blood or lymph node cancers like leukemia or lymphoma. Researchers collect medical histories, genetic samples, and sometimes perform exams to find inherited genes or environmental triggers. The g…

This study collects white blood cells from 120 people aged 3 to 65 with leukemia or lymphoma that hasn't been cured by standard treatments. The cells are gathered through a procedure called leukapheresis, then processed and frozen for future use in CAR T-cell therapy. The goal is…

This study uses bone marrow samples from 70 people with blood cancers to create 3D organoids—tiny lab-grown models that mimic the tumor's environment. Researchers will test different chemotherapy combinations on these organoids to see which kills the most cancer cells. The goal i…

This observational study at Mayo Clinic looks at how immunotherapy drugs affect balance and hearing in cancer patients. Researchers will test 50 adults before and during treatment to see if their vestibular (balance) system changes over a year. The goal is to better understand si…

This study looks at sleep problems in adults who had childhood cancer. About 200 survivors of leukemia, brain tumors, or solid tumors will wear sleep monitors and answer questionnaires. The goal is to find out how common sleep disorders are and how they relate to other health iss…

This pilot study aimed to see if giving a logbook to patients hospitalized for a stem cell transplant could help reduce feelings of isolation and psychological stress. The study was withdrawn before enrolling any participants, so no results are available. It was planned at the Un…

This study follows 18 people who previously received GF-CART01, a CAR T-cell therapy for certain blood cancers like lymphoma. Researchers will track side effects and how long the modified cells last in the body for up to 15 years. The goal is to ensure the treatment remains safe …

This study watches 242 adults with high-risk polycythemia vera (a rare blood cancer that thickens the blood) who have already had a blood clot. Researchers track health data like blood pressure, weight, and lab tests to see which factors best predict future clots. The goal is to …

This study planned to check how often the adrenal glands stop working properly after chemotherapy in adults with blood cancers. It aimed to measure cortisol levels after a stimulation test. However, the study was withdrawn before any participants were enrolled, so no results are …

This observational study follows 321 Italian patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who are treated with venetoclax-based regimens outside of clinical trials. The goal is to describe their clinical features and outcomes, such as how long they live…

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…

This study looks at how frailty—a state of weakness and reduced physical function—affects the risk of severe side effects from chemotherapy in people aged 70 and older with cancer. Researchers will assess 160 patients using various tests for frailty, muscle loss, and overall heal…

This study looks at how radiation and chemotherapy change the bone marrow in people with acute leukemia. Researchers will use special scans and collect blood and bone marrow samples to track these changes over time. The goal is to learn more about the effects of treatment, not to…

This study looks at how doctors and patients feel about a new approach to picking antibiotics for people with blood cancers who have a reported penicillin allergy. The goal is to understand what might make it easier or harder to use this approach in everyday hospital care. About …

This study tests a quick, non-invasive brain scan called Magnetic Resonance Fingerprinting (MRF) in children and young adults with acute leukemia. The goal is to see if the scan can detect early brain changes caused by chemotherapy. Participants also take a fun, game-like memory …

This registry follows 535 adults with moderate-to-severe ulcerative colitis who are taking or starting Simponi. Researchers will track serious side effects like infections, cancers, and pregnancy outcomes over time. The goal is to better understand the long-term safety of this me…

This study tests whether a special website and video coaching for parents can help children aged 6-12 who had leukemia or lymphoma improve their learning and school performance. Many children survive these cancers but may struggle with memory, attention, and thinking due to treat…

This study looks at the biology of B-cell lymphoma in children and teens to better understand the disease and long-term effects of treatment. About 128 participants will provide tumor and blood samples for genetic analysis. The goal is not to test a new drug, but to gather knowle…

This study looks at why people with HIV and certain cancers caused by KSHV (Kaposi sarcoma herpesvirus) may lose bone density faster. Researchers will review past CT scans and health records from 40 adults treated at the NIH between 2005 and 2020. The goal is to find factors link…

This study follows 201 adults with chronic myeloid leukemia who are taking asciminib (Scemblix) as a third or later treatment option. Researchers want to see how long patients stay on the drug and how well it controls their cancer in real-world settings. The goal is to gather pra…

This study collects tissue and blood samples from 1,200 adults with known or suspected cancer. The samples are taken during standard surgeries or biopsies, with no extra procedures. Researchers will compare cancerous and normal tissues to identify differences that could lead to n…

This study aimed to compare a virtual voice agent with a human agent for teaching cancer patients how to use remote monitoring devices at home. Patients with lung cancer would have been randomly assigned to get instructions from either the virtual agent or a human over the phone.…

This study looks at how well the drug acalabrutinib works for people with chronic lymphocytic leukemia (CLL) when used in regular hospitals, not just in clinical trials. Researchers will track 350 patients in France for about 3 years to see how long they stay on the drug and why …